Whanin Pharm Launches 6 Variants of ADHD Treatment 'Whanin Atomoxetine Tab.'
Whanin Pharm has launched a new medication to treat Attention Deficit Hyperactivity Disorder (ADHD). The product released this time is named 'Whanin Atomoxetine Tab.'
This treatment is composed of a total of six different dosages, ranging from 10mg to 80mg, allowing for the selection of an appropriate dose based on the patient's condition. This enables patients to be prescribed a medication dosage tailored to their needs.
ADHD is a condition that can affect not only children but also adults, making consistent treatment and management very important. The launch of this new product is expected to help improve the treatment environment for ADHD patients in Korea.
Whanin Pharm plans to further strengthen its position in the pharmaceutical market through this new product. Attention is now focused on whether the company will continue to demonstrate tangible results by developing a variety of medicines for patients in the future.